{
  "casebody": {
    "data": "<?xml version='1.0' encoding='utf-8'?>\n<casebody firstpage=\"995\" lastpage=\"1001\" xmlns=\"http://nrs.harvard.edu/urn-3:HLS.Libr.US_Case_Law.Schema.Case_Body:v1\">\n<p data-order=\"0\" data-type=\"docketnumber\" id=\"b1043-9\">52 CCPA</p>\n<parties data-order=\"1\" data-type=\"parties\" id=\"b1043-10\">Application of Harry Louis YALE, Francis Alexander Sowinski and Jack Bernstein.</parties>\n<docketnumber data-order=\"2\" data-type=\"docketnumber\" id=\"b1043-12\">Patent Appeal No. 7403.</docketnumber>\n<court data-order=\"3\" data-type=\"court\" id=\"b1043-13\">United States Court of Customs and Patent Appeals.</court>\n<decisiondate data-order=\"4\" data-type=\"decisiondate\" id=\"b1043-14\">July 19, 1965.</decisiondate>\n<attorneys data-order=\"5\" data-type=\"attorneys\" id=\"b1044-11\"><page-number citation-index=\"1\" label=\"996\">*996</page-number>Lawrence S. Levinson, Westfield, N. J. (Robert Alpher, New York City, Merle J. Smith, Scotch Plains, N. J., William H. Saltzman, New York City, of counsel), for appellants.</attorneys>\n<attorneys data-order=\"6\" data-type=\"attorneys\" id=\"b1044-12\">Clarence W. Moore, Washington, D. C. (J. E. Armore, Washington, D. C., of counsel), for the Commissioner of Patents.</attorneys>\n<p data-order=\"7\" data-type=\"judges\" id=\"b1044-13\">Before WORLEY, Chief Judge, and RICH, MARTIN, SMITH, and ALMOND, Judges.</p>\n<opinion data-order=\"8\" data-type=\"opinion\" id=\"x999-1\" type=\"majority\">\n<author id=\"b1044-14\">WORLEY, Chief Judge.</author>\n<p id=\"b1044-15\">This is an appeal from the decision of the Board of Appeals which affirmed the examiner\u2019s rejection of claims 12, 13 and 18 in appellants\u2019 application<footnotemark>1</footnotemark> for \u201cTrifluoromethyl Phenothiazines.\u201d</p>\n<p id=\"b1044-16\">An understanding of the issues here will be facilitated by setting forth a summary of the proceedings leading to this appeal.</p>\n<p id=\"b1044-17\">Appellants\u2019 application, along with applications of three other parties, was involved in two interference proceedings <page-number citation-index=\"1\" label=\"997\">*997</page-number>in the Patent Office relating to priority of invention of certain piperazinyl-lower alkyl-trifluoromethylphenothiazines, useful as tranquilizers. The subject matter of the interference counts is represented by the following chemical compounds:</p>\n<p id=\"b1045-4\">\n<img class=\"p\" height=\"366\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAA90AAAFuAQAAAAC0dEbZAAAWOklEQVR4nO2dT4wlx13HP92vM68dxjMdRUrGaJ1pR5FyQeKF5LAQx69tLBIkhDhzyRAhFAkJbVCAjbB3ap2RYgkJ740cQjK5gMSJ3HxI7NrEKHsI8UNESEgkro0HeUAR6VkGu+e5XxeH/lfd7/979WZXyv4ur6u6qr7151e/+tWv61fP0Uyhi69IOe2dHbpwpoLf/q3H1IbBvamvos0iA7jTXmiI7xt4tmnkWeCXQQ8meNqJ7x84V/z7CB5On4WbB78EmgWe3DdwT20aelbL482PSIVwq/0mYePsXoF/QbReDJ8INg1ezieNbL5wdBxvGrxseYZqvRH3No1dgaectt4ctNWM2xsDPyVtvdkjbIRHUYhlKsGPGbXetKVrugHlQucE9HWTxG4jGNPVdikpWq4JGTQqNeR6s5aDsYFZmwrwe3yWJne/w1ZTtkeMxGbAY4ScnVATtEWBLXDl0NNR85XTCA35k9bAWKCC3zo6Zb/BX1o3GEyhJdoqFQx3xpO4rakkmpU87tCz3fAcPCbSkclxWoyl3Ma3vovRWmstHZ3um70a91U/636vjsjY11lzYGx1u9zinJCgqtIA7mS8UtdxSHjujMn/NckF0GKPON7jvIqWkH7b79fpTpH/gxpuAHxISIhX78+0gNFnzJ2q6vBGFEzdT68BniBH0BFV2WULB1W6aBuUbY5zAQZdUgKiquw7xVMlYDU9oMsd++Ayh5FVSyUC4cThRZnsp0iIkXbXFhcYCZ8BIXt1Sx2cA5e9ups7QEKvveivSVrrhL5mV+uvlcI2o6t1emhMbNXVWjk6HVv015rnaK0VBYzgMIcqQSt9gl2tY/Y1u9oeJS6gOgV7R8WiqTjIuyU6y39HXAOfGGF3/5Y3S3GotZZFw6RTdUw/7wpHa52xq5XNhS0hR5CdPGT+aF0Nev5aODopBsYOuAsJEfIHAFu5jEvYLrrFEUX3ewAHWmzZ1Wa0VuiUN/IWcqi1VjVPq928A/p5j9jluMQF1alWlJBj4LhuXvB/AFkesUWMtMpxWrNfcVjCrtYap64ch1rrOOeBjI5VjktcNGHVUo9zuDAsBh7HwCDfvTiMuNLaRK3Z8hhdj6RwtJbG1iSjq2tZk7KfWRz0xCV20JUOc6Aj4GpVNUemoEX5mtixaSZyweVeKdEIGCDNVbuXGXt3l4TYpjajRdfgooSOrkRM3tOHOqkiJDbFTEJKX4uavXGSBnjGvq55IKaf2lNhE/ecCLFVdYTQtXwDcESs2StD2wzae4u1SDUFtiJu9qtyflZHZHS1tLZNT5BdbcIlRE0xEjuqHhQtuqXEsQHu4hOX6wfgIbuNntmBelCIdOTbU6Vc2SM0DJ0dWoZH51AZEb2h6ra3kGuAI3WDw2R7MxpxrQ74C5gRFifPYdiA67VX7DA09ikeCQev2gJ3XZIGnN9tpdjrGIGOHBIoa+AwaNg/xj5uNCNCLfzYIrjcMcKJOyGFQVatQm2s/x6ztjXtQtsMPGvrmptRL5jAG3PSd4xN/PrgLcuPnDfo0h42LjjKjBDtFC2DQM8u+B/NTuE0bX++xc/LLvWCCZM/2b9sBrZwrX34WeT7lTADjsjscXsbXbRT6FZDn7H3ycsdA5tHH7EFDe4Y/4yZXVrsvtd+vwb4WMzYPHfGkmwO/BJpPvjmGr5Iyzf3GX2Fbrc3UvNLas9zi8d3xoTMZVIbe4PsNQF8rBM3fzymBm+FLZvzlwMfn1n3d57fV/D7K2TE8lkWBH9hfpqN8f8KLbeoRrXCT1zG2ccKfAEw0cqyMe11gpDZnMgbX1isH8uYAT43YoMT/YGScGpcex1ruL2pFs1N4rc5zh63S1slrQK+QJrLY7hLlXDzk2yQ4eZGjJFF1dlaSauAt9vxgI35BjWZVji0VvIC5DjNfr77oUfazOy32FuPpViRLhZZUkUzuDluV9ZKXgT8Mrl7DLwdMV6ZsUXM3qrWQg9tFbwQ+ApZNifbxzQZvcG9mmiG1YQ0YkKcHfAV8thjuDZ3X+ae+YFSncfn+ZhZZJPKxNzt0gYtkAsYC+yBP0gWyPsMvnkfueng91OBlEuOw2Ad/WPdMf+W89g/WgOPlswvOL0+P9WC4EvS8Vq5x3l7CYPQxUfjtcDHWi7GkozHlHRnXet8Jz00zyv9bzp29KnbOomVVWF2dwWr+1MlLqk067I9gQlenFJvTcL1rlq94R5tp6AxLhBRIzgylh4NfrC6YuPeaHlrjUs40WsEzdMiQ+itoVS5etlvOrHUz+8CRT2jv1tdq3I5arJzetFK0a7bcZQd3XOc9/mkuwo4WxkbN/puW1KIZjBL269TgDglCQLWOvzs8i9Np6AX5xzDueAGkJ+XCf0RkZiVeg54mDT9Q0R7lUqbxw6TTs5xA4jZQry6hqBxg2FoMrim7R31YnOxGWzH+YOHIqudfVYC9/WeWffhWHHiQJlBGRznR5T8fAm8s8YXR9fjWTPsEzcd5TRB3MjxWbH/O72nk/xsdudodWggY8c49prhJE1HmYTYOPeq3xW5I02K1lKn+yndl1aX7Q4X6sioypZXcVwMcNrdMYcleyIlAtwiMsU8HLokucSjvZrjUnw357gX4EcAas8xOe5vvn6nI8g3UU/ghvzGytDg4qdfqcVMQuCIIcBhdPYUue+1GtTp4ygyVh5H8p41vka5eByLuAwOOChO96NiDaSOJDDXkufr80l5z6+h57t0iK9XIjJyROVioADuuJgr3dA5t2iqc0Ge63Jqa1zYzVf4GAB5BQyOe8uN2/M6ZfToquhaK9LyVHnuxyK6Wmt233R04aBWH+aXXeN4+12tddLvrOxpkLiwx2+W5rdTrgEH+ar66Ocgn1eqkrjRX0S18qDREZHgzqpHQl3YQpUcd+wIyL0DReIPKvNLydEX3JgwreXK7tlaZ3RVobLmmmjKvtayk36ydBzKymGJncQ496902k8Ov5+tqsAmLji9YZAvm2e5lavDKVwFD4Li6HuU/wy2zCUvECjk1dX3tS5wR4u89Lg4UiuGwCsoRnmEU04v6R+/z8gs0/DqPdYw2GqtU57M+bn0w5Yc6uRuul+5WhQsntI3vViSftIHnXbHNxoLdzsu/8oJgCzO0fc4zuXXoHC16OX8n/KpRisVGgS+efx+GXIBh3OZAReiEJXbxCTihdpUsJ1rlYnzRXNWeXESAW6wIna+URRZTwNJebWEyzkEEl3Wxs0x462GfHOTAYCjVrWluAA39E6jOzOZ4ZMxLG28xWHrcE81tnJp5Kxlky4Ki4ghqArq6QhfkThxEaHuARc8bq6nOCM4W2PPkIPnDdNUjhw+KvFc4xqhQAOnSMOPDhCInR1WP0SXFy8TmZBVK3XHI8aNOa7auU0IdM6bUjzK92zcW9G4kmcLh1fhvB73Ti7UhV8niwGv6XVSph8Fq2EXekjAEQwMXS1+v+/AzQ+VYUd+GoI9udXIfKUHQLqyNlOIrv1d0x1VJ53k8K/3v19HxI7W8Y3JXnrJis57hc9Mh9N4hOFM43lgemnia8HujcqRskHJqsK9YBWRkhp3XND5KnzJTOdxDCeTJ/XKtolyno9E0nApOWil64gYjqfty9SU+MXAe8hBe740FfLoHC12mEwrXvtRIO6goibLJjzfCIcjMnNgDOqueoytAHfE3dbQtW/T2CM6n8xvkK2zsADRmGOQDBvBLoO4IyYXsuoWvQTv4cjGiyRqpRTvTL8l8HA98B2awmvc7/ZgOH1OReuBO23/FNW2SAR2PbZM8PYQI9vt3LHrqwYw9b5XR5/tx82YztQZdbs/7c0supi1EgfNoLL+xW0q+Jfxw1ZdrJ++nQr+LF3ZjNmJp5Yip75ZDfzqWIx9/4LpFwxvvpSZDLcgjcL1tNe1KI2HK46Ije/nZ3dWLMXCmF/4TBc/MzNOr/NFtHgxK4qf6eCJ2izyTPBlaFworAseLlhER1qXcEtoCB9f9QYEG92+HdkHlysWaQV88/QQ/CH4Q/CH4A/BLxn8EryxH9CWb/zvAh7Ylv/ijvlD8F888K1o4+B2zCKrkQ2zyOr0EPwh+KWSFUuyfvo7z7361j/8+dPauM5yAbIxz3XdfX25RL4Z83xx09rKp3Smg78dLVqGUU1lCVwvXNDK2t4Mbo8XLSOe+LgAWeH2/jdfCvWbv9f+Z5FLAVfR/i0ARu/uLpXRipARZWFby1mfZ4AHy9diSaO/Db3dgLxhCXxx+u6qGW3s1UT9uJywttBybcyY5TwcLICboj2Ulwy++jFvGwxnzIvAEvjCUy0xEH1lB3xxCuvH5aS1DfDIeI4vGdzEW+4yBAvgSqya0wK4NJ6dpebddO314qNqsSIa1xYsc12I9V2qWCaxhYVl9frbtsMtdVpn/W7XDcESCjvg4WIlZM0uknbAF6Tm5AqWybo+uLmuLEnrgw8aoaXYdH3w5kE6bzA51YbA1yAL4NEGwBfVC0SzvGXW1LVbPmqiL7WsTQdftFqt/dkyNpK1DUIXjzThllhTLSyprRKWOfy7PniLMaPLBE/aMk1cIvgqNgRr4GeqGQ4vE7xdQLBE3rWn2smVZvii/U820+ni4Qeeh+DTaNT8x2C5YXAdcYviypWTi/PfHkUSYBRFYf8Tn9kwePba4My7HQDw4yh++bmfAHA+eOOu+udyfo3Qh9EScNVtHVrMBD/JXhaFVU9HCSQnCmDwjrlmp3+YvaBm450eF+P1U5Kj9E+L2Oxm9FI4/T8ZFV+mI8h96VD0cpc44V7hCh8v/d2ctPHfhq+3Com7r4vd3Jk4403lxLWb/ZP401uu6vUphVojz6BeR9sa28d4rbHExsOXRZLnH/ITZZpQ1IR/t6pIAl5UhoT58OHp3u7RpxpBpTXIDOA0X+pFWet05lS7jtgLi5QEPLsdAri4PF11Q9zMomm5BkcI0pxxVMsq7M1SkL/yzl9df/VKrh7unu10v/z+awDv+a9fVfvPPFUkCrQ7ax3TBUpOtap5L3NgxpgXf0aSO4f2VJWxebP3LjelqoMZY33pmKhbRUV//kEfCKaCZzheuf+NJZC7aJ/hNZRlIZ8wQi6Idl+KvSh3CLtC6PueADgebvHhGWOe5pWMAe4a8UE7oTKeHRlfM8+6Z07C9bCXO4R9jj22fglAC25yGzWd4ULSEqv1HUO10hnUw4/MsOtB4YckbzYY7CY3Zy4sgobTZD4EoQvsT61Ki7wOpYOCMVjDYmWat6qF+U+AX091M0/Lv6/174CpX8uhF5pKtUt/DnhRkJkrqh8FjDe8LfNS8hZoD12uCklHIJjdco/bYfHgi7NfBiDG4XEnBNBH70Q4LV150ia1nJxVvePtiBvRDHAPPl9LMAfeysdfEBbjl43eO/5f7K80gwEYTik1WA/9mpwx1fKcRb4t6s6XdVEpxMrM5Yd5M8vODzliGFeB0QkA6pqvGIl5DJe/FqCNHn2zypVR3g5RUi6/o599vYz4DN/Pq+cTZOchZYF16YuQITxkiQxpY9oVRjmtfvzHt4uYXt1l1fdtiReDMxs8OfxhVdHOp6vo8Nd/QlX1J5uWCQGcuXejJPpSUPa+CFvlOuTcNws89itWzvDK+hNl5uRuGiLielq+mBQQeSEO4FYM73JbzAb/UfkgeLduX+sgR9NNb5IH5+MB/Fr+2P37+k7BZ/WMqaaQiSybnoi8HHNdccEDHZi5fKSpYfgS+LDPSAPcwf8g+tEiwydntTyHVZw9UvG5PokQRT/fDNiT0PZYbt6alhSm2RPnGPh2BmQk5Mw2a6qVCuQgEeVYDkvdTaHFufPWVR+41UATqrXqvuwDaiemmh4pUTEjpwuZGHwIkYUCCJxyjsxVsowMtmLwm9zuevDI208Bnl+2PlEMvkiSgyVkuAWbzhCvBScVlwTmRWUU45Gicw72ZCObA2w9clv+Je/2iuwQyrNKe4zRZMVAzvi6lHmQi6w+SuSXAGpUgkMtPyNeb2aLAegfXSABBT4+gswpqo5bzsYZQsZN8ZMIMq7F5b8Ry4+Q/0FuyGBfion5ypmUy4JYA/TJIOUFIFCPQt75MzeKJ9zCvUP3xST825ujP9Na8PscvdOLlFS3OAiLSk4tgGoxlV3nkCzveNmTEnLxM1Vvd3S4z4uPpqm/lQYnnTQdDhH6mVeG6vnuk0+/9C1xJgFeaYlXRMNnMMlIVC7qNEAWd+RZtRxMr7ggFJxn4AgfDwTSoSfLuuWHBEaHYlbLvWHqAwMfB3EDFzjCB/xRn2dmgB8QidSDoBbfLr6TKxJJ8V+6acvcGbVsr/rzcBq/HaDhyAPOyBsSIEbRdPAAAe8lCcHLBy/yALGFJ6dddq4Hx2ET/TjwUWleL+4FRQ0BRtEMvX27S/cIlwjRoedxlFuzD/aAyKcS4U2wuBHqQJjfCeIAfhy65EpJEiJnbRQ7CdcHvX/3hYbvfbvzc/djQMKV0P0P+rdOilTtf09tfeKTUeTtQYhLSBDIQtTILwDG5UwTqcdXAfgVQeD8ELilOtIBDopKex9paq9bftNQFTqiI0IiICB8hHz2BYNBBxZQo95DVu2Ci41DDpwGQOd74kNGYmfsuuEt4EpXINlGbuEwIME/j1DPwHSbTEVpZXTZT6t7QV/XcX9SYp0cNmwy+1prvat/2NVZR2utv6G10Cn0E/21vQXA8wIKM05dtJgMnk6MFV2t98sydAaHWuuXFwBXNXhcJ1fNy1FnU2bcGhijNR2tq6ubZtHI4KiglqVqmU85xm0wOnJA5lcNzgc3bvHSPFVFy2W+5Bi7x0y5EAYLgsd1E4f1PNJi8S8KQHXXG6n/A7hyUJQyj2SdJKkv9Mo6LxUPiwy9wbPx43Vx81su6/2Qmdq7VjyoZvLmRcwFDQ7qZ3fi4xTq1KXH9cec6oxIFjeTn4gJZRhaTxwa8XO7zLhaU9VdnJYdmbau3pSTyjDuiZSHy3S7IS9VVD1W++WFtrnbEzthfl5zO2S4S9STp2UImXTcuVGGET8X3NyFGva4aujaYHJyMRMvn57fa6EZOKkfR2Ji8okF/udj1Qlscbfuv7ng6eiwGvWR83iV8RPlVqVVh0lVytLTeiOtjM6Zx+zJVSpehWo1kZQXAd6eOjnqqWHgGGUswO2Tz55E1VPDJrPcMe+54Mmg5jkxEUNg0qTDUZ0pJ6ZW/5wpJ8ZmwaTYf6vnozB6be45IN+c3RU53Q+EYf4YNGox+YzOE7qakZG4XZU3F7z7RljNr9999ZvfKB6TySsISTgx2vlA+dQ3T0nO4/a5lOybofhwiZzrf8Ju9l28TNb1jy3o95mAd/enpRsnG8cWGoJALZPTAniDweXlgjszQvOyrn9UxUunBeaQjTE3/ZUu34PHDCzlUWGh283ZtdTfmdo+IZRNWb8mkw1wYTwHlwxuLmtpeMngpsvQci6qlsc8ji4Z3JxdSlwyuLmMyqUyWpjn5pq61F/uWpnnm3CEXpTMg93LFWej5ct5wloGr9lGL7WuWAGPxIoZ7QqZ5dYVK+Dhtwrl6dSaa+jiFAz4g47zMcd57IvhcjnX3rHk2++CltivWNmxrNF7lm/YWKo0O2pUWD48t1w+O0fMX/vOSzGjf3pqfkqTLv4fTsE3fKJAMa0AAAAASUVORK5CYII=\" width=\"989\"/>\n</p>\n<p id=\"b1045-7\">10[3'-(4-P-hydroxyethyl piperazin-l-yl) propyl3-2-.trifluoromethyl phenothiazine</p>\n<p id=\"b1045-8\">\n<img class=\"p\" height=\"354\" src=\"data:image/png;base64,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\" width=\"1019\"/>\n</p>\n<p id=\"b1045-11\">10 [3' - (4-p -acetoxyethyl piperazin-l-yl) propyl 3 **2\u00ab trifluoromethyl phenothiazine</p>\n<p id=\"b1045-12\">\n<img class=\"p\" height=\"359\" src=\"data:image/png;base64,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\" width=\"1017\"/>\n</p>\n<p id=\"b1045-15\">10 [31 - (4-p, p * -hydroxyethoxyethyl piperazin-l-yl) propyl]-2-trifluoromethyl phenothiazine</p>\n<p id=\"b1045-16\">It appears from the record that the above tranquilizers may be prepared by various processes, one of which involves reacting the desired piperazine derivative with a phenothiazine intermediate. During the motion period of the interference proceedings, appellants moved to amend one of the interferences by adding the following proposed count or claim, directed to the phenothiazine intermediates <page-number citation-index=\"1\" label=\"998\">*998</page-number>useful in the synthesis of the tranquilizer compounds, to their application:</p>\n<blockquote id=\"b1046-4\">10- (3-halopropyl) -2-trifluoromethyl phenothiazine.<footnotemark>2</footnotemark></blockquote>\n<p id=\"b1046-5\">The examiner denied appellants\u2019 motion to add those particular phenothiazine intermediates as an issue in the interference, stating:</p>\n<blockquote id=\"b1046-6\">* * * The proposed count which is directed to the intermediate for the final product, which forms the count of the interference, does not involve a distinct and independent invention. The preparation of the final product via the intermediate of * * * [the proposed count] involves a single inventive concept for which only a single patent may issue. * * *</blockquote>\n<p id=\"b1046-7\">****\u2022\u00bb*</p>\n<blockquote id=\"b1046-8\">* * * Moreover, the count is deemed to be so broad as to be unpatentable to each of the parties in the use of the term halo which is</blockquote>\n<blockquote id=\"b1046-11\">not properly supported by any of the parties and which has not been shown to be suitable or operable in the inclusion of the fluoro derivative.</blockquote>\n<p id=\"b1046-12\">No appeal of the examiner\u2019s decision could then be taken by reason of Rule 244(d).</p>\n<p id=\"b1046-13\">Appellants subsequently conceded priority of invention of the three phenothiazine tranquilizers at issue in the interference proceedings. Upon resumption of ex parte prosecution of their application before the examiner, appellants continued to seek a claim to some of the phenothiazine intermediates of the proposed count by amending the proposed count to exclude fluorine from the scope of the expression \u201chalo.\u201d The resultant claim is present claim 18:</p>\n<blockquote id=\"b1046-19\">18. 10-(3-Halopropyl)-2-triflu-oromethylphenothiazine, wherein the halo has an atomic number greater than 9.</blockquote>\n<p id=\"b1046-20\">In addition, appellants persisted in prosecution of claims which differ somewhat in scope from claim 18, corresponding to claims 12 and 13:</p>\n<blockquote id=\"b1046-21\">12. 10-Halo (lower alkyl )-2-tri-fluoromethylphenothiazine, wherein the halo has an atomic number greater than 9.</blockquote>\n<blockquote id=\"b1046-22\">13. 10-(3-Chloropropyl)-2-triflu-oromethylphenothiazine.</blockquote>\n<p id=\"b1046-23\">The examiner rejected claims 12, 13 and 18 on certain prior art having effective dates prior to the filing date of the present application. The board, in reversing that rejection, accorded appellants the benefit of earlier copending applications <footnotemark>3</footnotemark> which, in the board\u2019s opinion, adequately supported the subject matter of the claims. The board, however, rejected claims 12, 13 and 18 under the provisions of Rule 196(b) as unpatentable over Ullyot,<footnotemark>4</footnotemark> the winning party of the subject matter in interference in which appellants conceded priority. It took the position that claims 12, 13 and 18 are drawn to intermediates which are obvious to one skilled in the art as being suitable for the preparation of compounds of the counts in interference, now claims 1, 7 and 11 of the Ullyot patent. In support of that position the board referred to the Cusic patent<footnotemark>5</footnotemark> which shows <page-number citation-index=\"1\" label=\"999\">*999</page-number>that certain piperazinylphenothiazine tranquilizer compounds of the formula</p>\n<p id=\"b1047-6\"><em>F, Cl r~\\ </em>alkylene N \u2014R 0</p>\n<p id=\"b1047-11\">may be prepared by reacting the desired piperazine derivative with a phenothiazine intermediate of the formula</p>\n<p id=\"b1047-12\">alkylene-halogen</p>\n<p id=\"b1047-14\">In addition, the board relied on the disclosure of Ullyot, who states that 10-(piperazinylalkyl) - 2 - trifluoromethylphenothiazines may be prepared by reacting a 10-(haloalkyl)-trifluoromethyl-phenothiazine with the requisite piperazine. The board also noted that Ullyot sets forth two phenothiazine intermediates, 10- (2'-chloroethyl) -2-trifluoro-methylphenothiazine and 10-(3'-chloro-2'-methylpropyl) - 2 - trifluoromethylphenothiazine, which fall within the scope of appellants\u2019 claim 12 and are homologs of the compounds of claims 13 and 18.</p>\n<p id=\"b1047-16\">With that background information, we now consider the arguments advanced by appellants in asking us to reverse the decision of the board. In the main, appellants contend the board erred in two respects: (1) in holding that the present claims are not patentably distinct from the counts of the interferences, and (2) in holding that the counts of the interferences and the disclosure of the Ullyot patent are \u201cprior\u201d art against the appealed claims. As appellants\u2019 last contention presents the more serious question, we shall discuss it first.</p>\n<p id=\"b1047-10\">Appellants point out that the board held they were entitled to the filing date of their earliest parent application, December 23, 1955, for the claimed subject matter, and that the Ullyot patent relied on by the board was filed May 13, 1957, some one and one-half years later. It is appellants\u2019 position that, based on the above facts and the only evidence in the record, appellants were the prior inventors of the subject matter of the appealed claims.</p>\n<p id=\"b1047-17\">To discuss the merits of appellants\u2019 argument we turn to the pertinent portions of 35 U.S.C. \u00a7 102 and \u00a7 103, as well as decisions of this court. Those statutory provisions read:</p>\n<blockquote id=\"b1047-18\">\u00a7 102. Conditions for patentability; novelty and loss of right to patent A person shall be entitled to a patent unless \u2014 \u25a0</blockquote>\n<blockquote id=\"b1047-19\">******</blockquote>\n<blockquote id=\"b1047-20\">(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or</blockquote>\n<blockquote id=\"b1047-21\">******</blockquote>\n<blockquote id=\"b1047-22\">(g) before the applicant\u2019s invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.</blockquote>\n<blockquote id=\"b1047-23\">\u00a7 103. Conditions for patentability; non-obvious subject matter A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would <page-number citation-index=\"1\" label=\"1000\">*1000</page-number>have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. * *</blockquote>\n<p id=\"b1048-4\">To be sure, the disclosure and the claims of Ullyot corresponding to the interference counts are not a reference under 35 U.S.C. \u00a7 102(e), since appellants\u2019 effective filing date for the compounds of the appealed claims precedes that of Ullyot. However, as noted above, appellants have conceded priority of invention of the three chemical compounds set forth in the counts in interference. Under the proper circumstances, a concession of priority or disclaimer of interference counts renders those counts available with the same effect as a \u201cprior art\u201d reference disclosing such subject matter. In re Williams and McCabe, 62 F.2d 86, 20 CCPA 738, and the counts may be combined with other prior art to show lack of patentable distinction between the counts and appealed claims, In re Sola, 77 F.2d 627, 22 CCPA 1313. The 1952 Patent Act did not change the force of those decisions. As we recently pointed out in In re Harry, 333 F.2d 920, 51 CCPA 1541, the legislative history of 35 U.S.C. \u00a7 102 and \u00a7 103 makes it clear that the \u201cprior art,\u201d which section 103 requires us to compare with \u201cthe subject matter sought to be patented\u201d in a given situation, refers to at least the statutory prior art material named in section 102. It seems clear that the three chemical compounds which appellants lost in interference by concession of priority are materials of which it must be said \u201cbefore the applicant\u2019s invention thereof the invention was made in this country by another.\u201d Those compounds become \u201cprior art\u201d within the meaning of 35 U.S.C. \u00a7 103 and, in accordance with that provision, appellants may not obtain any claim which distinguishes over that \u201cprior art\u201d only in matters which would have been obvious to one having ordinary skill in the art <em>at the time appellants\u2019 invention was made.</em></p>\n<p id=\"b1048-5\">That analysis, however, does not completely dispose of the issue before us, since it requires a finding that the compounds of the counts were invented before the compounds of the present claims. We note that the record fails to establish <em>any </em>date to which Ullyot is entitled for conception and reduction to practice of the products of the interference counts, much less whether that date does in fact precede the date of December 23, 1955, to which the board held appellants are entitled for constructive reduction to practice of the presently claimed subject matter. That void in the record apparently arises from appellants\u2019 concession of priority of the interference subject matter. We are unwilling to view that concession of priority of invention as extending to the distinctly different chemical compounds herein claimed. As noted earlier, the final products of the interference counts can be made using processes and intermediates unrelated to the present compounds, and it does not necessarily follow from the concession of priority as to those final products that the winning party, Ullyot, invented the final products before Yale invented the compounds of the appealed claims.</p>\n<p id=\"b1048-7\">We agree with appellants that the particular circumstances of this case preclude a finding that the counts of the interference, directed to the piperazinyl-propyl-trifluoromethyl phenothiazine final products, are indeed <em>prior </em>art to the subject matter of the appealed claims, the halo-lower alkyl-trifluoromethyl phenothiazine intermediates. Since 35 U.S.C. \u00a7 103 is very specific in requiring that a rejection on the ground that an invention \u201cwould have been obvious\u201d must be based on a comparison between the prior art and the subject matter as a whole <em>at the time the invention was made, </em>we think, on this record, the board erred in treating the counts as \u201cprior art,\u201d and its decision rejecting appellants\u2019 claims as obvious in view of those counts must be reversed. See In re Taub, 348 F.2d 556, 52 CCPA -, decided concurrently herewith.</p>\n<p id=\"b1048-9\">The next question is whether the disclosure of the Ullyot patent also constitutes a \u201creference\u201d against appellants. The board did review the pertinent dis<page-number citation-index=\"1\" label=\"1001\">*1001</page-number>closure of the Ullyot patent. In addition to disclosing both generically and specifically several 10-(piperazinyl-alkyl)-2-tri-fluoromethyl phenothiazines in which the alkylene group linking the piperazine and phenothiazine rings may be <em>ethylene, propylene </em>or <em>2-methylpropylene, </em>Ullyot discloses synthesis of those compounds by reacting 10-(haloalkyl)-trifluoro-methyl phenothiazine intermediates with the desired piperazine derivative. Two specific intermediates employed in that synthesis, the 10- (2'-chloroei/M/\u00a3) - and the 10- (3'-chloro-2 <em>'-methylpropyl) </em>-2-tri-fluoromethyl phenothiazines, were disclosed and synthesized in examples.</p>\n<p id=\"b1049-5\"> Unfortunately, it is not clear from the board\u2019s opinion whether, in relying on the disclosure of the Ullyot patent, it applied the well established principle of estoppel that an interference settles not only the rights of the parties under the issues or counts of the interference but also settles every question of the rights to any claim which might have been presented and determined in the interference proceeding. In re Chase, 71 F.2d 178, 21 CCPA 1183; Avery v. Chase, 101 F.2d 205, 26 CCPA 823; In re Gregg, 244 F.2d 316, 44 CCPA 904, and cases cited therein. While the doctrine of estoppel has been applied where a party has neglected or refused to contest priority of patentable subject matter which is <em>clearly </em>common to his application and the application of his opponent in interference (see In re Long, 83 F.2d 458, 23 CCPA 1078, and In re Rhodes, 80 F.2d 525, 23 CCPA 816), we can express no opinion on that issue where it is not certain the board intended to raise it, and where it is not clear from the board\u2019s opinion whether it regarded the Ullyot patent specification, when considered as a whole, to <em>clearly </em>disclose the chemical compounds recited in appealed claims 12, 13 and 18 (In re Rhodes, supra; Lawson v. Bruce, 222 F.2d 273, 42 CCPA 893; Binstead v. Littmann, 242 F.2d 766, 44 CCPA 839; 113 USPQ 279; Mahan v. Doumani, 333 F.2d 896, 51 CCPA 1516). Nor did it discuss appellants\u2019 contention, made here as well as below, that no question of estoppel arises against them, since they unsuccessfully attempted to amend the interference under Patent Office Rule 233 to place in issue a proposed count reading \u201c10-(3-halopropyl) -2-trifluoromethylphenothia-zine.\u201d Compare, for example, American Viscose Corporation v. Coe, 70 App.D.C. 328, 106 F.2d 849, and Power Patents Co. v. Coe, 71 App.D.C. 369, 110 F.2d 550. Under the circumstances, we think it necessary to remand this case for clarification of the board\u2019s position with respect to its use of the Ullyot disclosure in rejecting app\u00e9llants\u2019 claims.</p>\n<p id=\"b1049-7\">The decision is reversed and remanded for further proceedings.</p>\n<p id=\"b1049-8\">Reversed and remanded.</p>\n<p id=\"b1049-9\">SMITH, J., concurs in the result.</p>\n<footnote label=\"1\">\n<p id=\"b1044-18\">. Serial No. 683,219, filed September 11, 1957.</p>\n</footnote>\n<footnote label=\"2\">\n<p id=\"b1046-14\">. Those compounds may be represented by the structural formula.</p>\n</footnote>\n<footnote label=\"3\">\n<p id=\"b1046-15\">. Serial No. 554,936, filed December 23, 1955, and Serial No. 597,325, filed July 12, 1956. Those applications did not disclose the subject matter of the interference counts.</p>\n</footnote>\n<footnote label=\"4\">\n<p id=\"b1046-24\">. U. S. Patent No. 3,058,979, issued October 16, 1962, on an application Serial No. 658,526, filed May 13, 1957.</p>\n</footnote>\n<footnote label=\"5\">\n<p id=\"b1046-25\">. U. S. Patent No. 2,787,617 issued April 2, 1957, on an application filed September 20, 1955.</p>\n</footnote>\n</opinion>\n</casebody>\n",
    "status": "ok"
  }
}